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We tested the hypothesis that total body irradiation (TBI) given at a high dose rate would be more immu-
nosuppressive and lead to a higher incidence of stable hematopoietic cell engraftment after suboptimal levels
of conditioning irradiation compared with TBI at a low dose rate. We assessed the engraftment success of dog
leukocyte antigeneidentical bone marrow transplantation in recipients of 100, 150, and 200 cGy TBI
administered at a rate of 7 or 70 cGy/min. Dogs received donor marrow on the same day as TBI and were
subsequently treated with postgraft immunosuppression consisting of mycophenolate mofetil (for 28 days)
and cyclosporine (for 37 days). Donor chimerismwas monitored until the end of study and was characterized
by either graft rejection or stable engraftment. Increasing the radiation dose rate from the traditional
7 cGy/min to 70 cGy/min did not lead to increased engraftment success at any of the irradiation doses tested.
The dose rate of 70 cGy/minute was no more hematotoxic than the rate of 7 cGy/minute. TBI delivered at
a high dose rate was well tolerated but was not associated with a better rate of allogeneic hematopoietic cell
engraftment compared with TBI delivered at a lower dose rate.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Total body irradiation (TBI) of varying dosage intensities is
commonly used to condition patients with a hematologic
malignancy for allogeneic hematopoietic cell transplantation
(HCT). Studies in the canine preclinical model have shown
that high-dose TBI can be replaced by a relatively safe
nonmyeloablative dose of 200 cGy delivered at a rate of
7 cGy/minute [1-3]. This dose and rate have proven to be an
effective conditioning regimen for stable long-term hemato-
poietic engraftment in dogs receiving bone marrow grafts
from dog leukocyte antigen (DLA)-identical littermates when
followed by a short course of immunosuppression with
mycophenolatemofetil (MMF;28days) and cyclosporine (CSP;
37 days). Subsequently, these studies were translated to non-
myeloablative HCT for treatment of human patients [4,5].
Continuing efforts in the canine model to reduce the TBI dose
from 200 cGy to 100 cGy followed by HCT and intensiﬁed
postgraft immunosuppressionor the additionofmesenchymal
stromal cells, or preceded by procedures to induce immune
tolerance in the recipient toward the marrow donor, have not
achieved the level of success seen with 200 cGy TBI [6-9].
A previous study found that dogs receiving bone marrow
grafts from DLA-identical littermates after 450 cGy TBI at
7 cGy/minute usually failed to engraft long-term, but did
engraft when the dose rate was increased to 70 cGy/minute
[10]. The authors concluded that at this TBI dose, the
70-cGy/minute dose ratewasmore immunosuppressive thanedgments on page 1653.
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we readdressed the issue of engraftment success with non-
myeloablativedoses of TBI andhighdose rate conditioning for
bone marrow transplantation in the DLA-identical littermate
setting by comparing marrow engraftment after delivery of
100,150, and200cGyTBI at dose rates of 7 and70cGy/minute.MATERIALS AND METHODS
Experimental Animals and Typing
Beagle, mini-mongrel, Basenji, and Golden Retriever crossbreeds were
raised at the Fred Hutchinson Cancer Research Center or purchased from
commercial kennels. The animals were housed in Association for the
Assessment and Accreditation of Laboratory Animal Care (AAALAC)-
accredited facilities, and the study design was approved by the Institutional
Animal Care and Use Committee. Selection of dogs for DLA-identical HCT
required typing of litters and parents using highly polymorphic micro-
satellite markers within DLA class I and class II regions [11] and DLA-DRB1
gene sequencing [12].HCT
On day 0, HCT recipients were treated with 100, 150, or 200 cGy TBI at
a dose rate of either 7 or 70 cGy/minute from a high-energy linear accelerator
(Varian Clinac 6; Varian Medical Systems, Palo Alto, CA or 6 MV Elekta
Precise; Elekta, Stockholm, Sweden). Dosage calibration and irradiation
techniquewere as described previously [13]. Within 4 hours of TBI, recipients
received an i.v. bone marrow infusion from a respective DLA-identical
littermate at a median dose of 4.3  108 nucleated cells/kg (range, 2.2 to
6.4  108 nucleated cells/kg). Postgraft immunosuppression consisted of
MMF 10mg/kg s.c. twice daily on days 0 toþ28 and CSP 15mg/kg twice daily
on days 1 to þ35. All dogs received standard post-HCT clinical care, with
clinical conditions assessed twice daily. Results from previously published
studies were used as controls in which dogs underwnet HCT after condi-
tioning with either 200 or 100 cGy TBI at 7 cGy/minute and treated with
postgraft immunosuppression with CSP and either MMF or sirolimus (SRL)
[2,3]. Dogs treated with SRL were added to the study to increase statistical
power, with the understanding that postgraft immunosuppression with the
combination of SRL þ CSP is as effective as MMF þ CSP [2].
Transplantation.
Table 1
Bone Marrow Grafts from DLA-identical Littermates after Sublethal TBI Delivered at 7 cGy/min or 70 cGy/min




Granulocytes (wk)* Lymphocytes (wk)
Dogs given 100 cGy TBI
Historical group, 7 cGy/min
MMF/CSPy
E165 63 (9) 40 (9) 12 Yes Yes
E166 5 (4) 1 (4) 10 Yes Yes
E202 9 (3) 14 (3) 3 Yes Yes
E204 <1 (3) 9 (3) 3 Yes Yes
E227 29 (4) 31 (2) 10 Yes Yes
E228 12 (4) 16 (4) 10 Yes Yes
SRL/CSPz
G092 20 (5) 18 (7) 9 Yes Yes
G111 62 (9) 37 (5) 11 Yes Yes
G151 3 (2) 2 (2) 2 Yes Yes
G156 50 (7) 48 (7) 9 Yes Yes
G167 45 (7) 30 (6) 9 Yes Yes
Study group, 70 cGy/min (MMF/CSP)
G760 42 (12) 80 (10) 13 Yes Yes
G763 43 (12) 46 (10) 17 Yes Yes
G792 35 (9) 20 (9) 13 Yes Yes
G794 41 (10) 42 (10) 15 Yes Yes
G809 32 (6) 19 (7) 12 Yes Yes
G759 12 (8) 8 (8) 12 Yes Yes
G764 54 (7) 40 (6) 8 Yes Yes
Dogs given 150 cGy TBI (MMF/CSP)
Study group, 7 cGy/min
H014 43 (4) 24 (8) 17 Yes Yes
H016 38 (3) 28 (3) 8 Yes Yes
H124 37 (10) 23 (4) 15 Yes Yes
H125 58 (15) 57 (18) >20 No No
H133 58 (4) 55 (17) >20 No No
H135 56 (4) 63 (28) >20 No No
Study group, 70 cGy/min
G994 74 (32) 47 (11) >30 No No
G995 44 (9) 38 (10) 18 Yes Yes
G986 12 (6) 5 (5) 9 Yes Yes
G987 14 (9) 3 (8) 10 Yes Yes
H025 83 (11) 80 (9) >30 No No
H026 26 (5) 20 (4) 18 Yes Yes
G965 86 (10) 60 (11) 18 Yes Yes
G972 66 (29) 52 (22) >30 No No
Dogs given 200 cGy TBI
Historical group, 7 cGy/min
MMF/CSPy
E131 54 (33) 49 (32) >57 No No
E219 69 (23) 36 (23) >54 No No
E220 6 (24) 35 (24) >54 No No
E066 100 (23) 100 (23) >53 No No
E069 100 (16) 100 (16) 12 Yes Yes
SRL/CSPz
E912 80 (6) 60 (28) >56 No No
G004 100 (4) 60 (17) >56 No No
G014 92 (5) 60 (45) >48 No No
G018 97 (5) 70 (6) >48 No No
G082 80 (7) 70 (5) 11 Yes Yes
G214 100 (6) 60 (10) >32 No No
G132 30 (2) 50 (3) >3 No No
Study group, 70 cGy/min, MMF/CSP
H128 93 (5) 65 (5) 28 Yes Yes
H129 61 (3) 43 (3) 18 Yes Yes
H206 86 (8) 73 (3) >28 No No
H307 94 (6) 72 (4) >28 No No
H329 96 (12) 80 (10) 10x No No
H333 97 (5) 67 (15) >27 No No
* Weeks after HCT.
y From Storb et al. [1].
z From Hogan et al. [2].
x Died due to pancreatitis.
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The contributions of recipient and donor cells to peripheral blood were
quantiﬁed by ﬂuorescent variable nucleotide tandem repeatePCR, as
described previously [14-16]. The sensitivity of the assay was sufﬁcient topredict chimerism at a level of 1%. Complete blood counts and blood
chemistry analyses were performed following standard laboratory proce-
dures using an automated sampler (ADVIA 2120i Hematology Analyzer;
Siemens, Tarrytown, NY).
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Curves estimating the percentage of dogs that successfully engrafted
over time were prepared following the Kaplan-Meier method. The log-rank
test was used to compare duration of engraftment between dose rates. To
compare blood cell counts between dose rates, average counts for each dog
were computed using counts from days þ7 to þ21, after log transformation.
The averaged counts were then compared between dose rates using the
2-sample t test.Figure 1. Graft survival in dogs treated with 100, 150, or 200 cGy TBI. Bone
marrow recipients were conditioned for HCT with 100 cGy at 7 (n ¼ 11) or 70
(n ¼ 7) cGy/minute (A), with 150 cGy at 7 (n ¼ 6) or 70 (n ¼ 8) cGy/minute (B),
or with 200 cGy at 7 (n ¼ 11) or 70 (n ¼ 6) cGy/minute (C). Differences
between 7 and 70 cGy/minute are signiﬁcant at P ¼ .002 for the 100-cGy dose,
P ¼ .95 for the 150-cGy dose, and P ¼ .52 for the 200-cGy dose.RESULTS AND DISCUSSION
Engraftment
Data for dogs conditioned with 100, 150, or 200 cGy TBI at
either 7 or 70 cGy/minute for DLA-identical HCT are
summarized in Table 1. Chimerism data for dogs are pre-
sented as percentmaximumdonor chimerism, alongwith the
week at which this maximum was achieved. Percent donor
chimerism data for dogs receiving all 3 TBI doses are pre-
sented at the timewhen themaximum level was achieved. At
all TBI doses, if rejection of the marrow graft occurred spon-
taneously, recipient marrow recovery was seen. Dogs treated
with 100 cGy TBI at 70 cGy/minute and given postgraft
immunosuppression of CSP and MMF were compared with
historical control data [2,3].
At 100 cGy TBI, all dogs showed rapid initial engraftment;
however, sustained engraftment was not observed in any of
the dogs treated with either a dose rate of 7 cGy/minute
(historical control group) or in the study group treated at
a dose rate of 70 cGy/minute. All marrowgrafts were rejected
within 2-12 weeks (median, 8 weeks) after HCT in dogs
treated with 100 cGy TBI delivered at 7 cGy/minute. All
marrow grafts were rejected within 8-17 weeks (mean,
12.9 weeks) after HCT in dogs treated with 100 cGy TBI at
70 cGy/minute. Duration of engraftment was signiﬁcantly
greater (P> .002) in dogs treated at 70 cGy/minute compared
with dogs treated at 7 cGy/minute (Figure 1A). At 150 cGy
TBI, stable engraftment was seen in 3 of 6 dogs treated at
7 cGY/minute and in 3 of 8 dogs treated at 70 cGy/minute,
a nonestatistically signiﬁcant difference (Table 1 and
Figure 1B). Two studies of 200 cGy TBI showed stable long-
term engraftment in 8 of 10 dogs combined at a dose rate
of 7 cGy/minute. In the present study, we found stable mixed
chimerism in 3 of 6 dogs treated at 70 cGy/minute, which
was not signiﬁcantly different from the historical group
(Table 1 and Figure 1C). These conclusions come with the
understanding that a small number of dogs was used in this
study. For the dogs treated with 150 cGy TBI, we considered
an improvement in engraftment from 50% to 75% as clinically
signiﬁcant, and we had a 56% power to show a trend (1-sided
P value of .20). For the 200-cGy TBIetreated dogs, we
considered an improvement in engraftment from 80% to 95%
as clinically signiﬁcant and had a 53% power to show a trend.
We next posed the question of whether the 70-cGy/
minute dose rate is more hematotoxic than the 7-cGy/
minute rate at 150 cGy. We compared total WBC count,
absolute neutrophil count (ANC), and platelet counts in dogs
treated at the 2 dose rates and found no signiﬁcant differ-
ences in the depth of the nadir or the time to recovery
between dogs treated at 70 cGy/minute and those treated
at 7 cGy/minute (Figure 2, A-C). In addition, the rate of
diarrhea/vomiting was infrequent and similar in the 7-cGY/
minute and 70-cGy/minute treatment groups, characteristic
of MMF-related toxicity (data not shown). Furthermore,
complete blood chemistry values for dogs treated at 70 cGy/
minute were normal at 15 days after TBI (data not shown).
Overall, the data suggest that at 150 cGy TBI, a higher dose
rate is not more hematotoxic than a lower dose rate.These studies were undertaken to test the hypothesis that
a 10-fold higher dose rate of 70 cGy/minute would permit
stable long-term hematopoietic cell engraftment in the DLA-
identical HCT setting using suboptimal doses of radiation.We
must reject this hypothesis based on 3 outcomes. First, no
dogs treated with 100 cGy TBI showed sustained engraft-
ment, although the time to rejection was signiﬁcantly
extended in those dogs that received this TBI dose at the
higher rate of 70 cGy/minute. Second, dogs treated with
150 cGy TBI demonstrated no difference in hematopoietic
toxicity at a dose rate of 7 cGY/minute or 70 cGy/minute.
Figure 2. Hematopoietic proﬁle of dogs treated with 150 cGy TBI. Data points
are mean values for WBCc, (A) ANC, (B) and platelet counts (C) for dogs irra-
diated at 7 (n ¼ 6) or 70 (n ¼ 8) cGy/minute. Comparing the nadirs (for days 7-
21) in dogs treated with 7 or 70 cGy yielded P values of .24 for WBC, .27 for
ANC, and .68 for platelets.
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chimerism was no better in those receiving a dose rate
of 70 cGy/minute than in those receiving a dose rate of
7 cGy/minute.
Our results were unexpected, based on a previous study
showing stable allogeneic cell engraftment in 6 of 7 dogs
receiving 450 cGy TBI at 70 cGy/minute, compared with only1 of 7 dogs receiving the same TBI dose at 7 cGy/minute [10].
A similar study found reduced platelet and granulocyte
toxicity in dogs given 300 cGy TBI at a rate of 10 cGy/minute
compared with those given 300 cGy at 60 cGy/minute [17]. A
possible explanation for the discrepancies is that the
previous studies involved uninterrupted irradiation deliv-
ered from 2 opposing 60cobalt sources, whereas in the
present study, irradiation from a linear accelerator required
an interruption midway through the procedure to reposition
the dog for exposure of the opposing side. This meant that
the irradiationwas delivered in 2 fractions, which could have
blunted the immunosuppressive effect of the higher dose
rate. The relationship between dose rate and engraftment
was also observed in mice receiving either allogeneic or
xenogeneic HCT [18]. The foregoing ﬁndings suggest that
perhaps the improved immunosuppressive effect of a higher
dose rate is limited to TBI at doses >200 cGy.
Neither we nor others have previously tested the efﬁcacy
of 150 cGy TBI as a conditioning regimen in the DLA-identical
HCT model. Nonmyeloablative doses of radiation at 200, 100,
or 50 cGy have been given [4]. It was unknown whether
stable engraftment was linear or nonlinear; it ranged from
approximately 80% at 200 cGy TBI in the 2 studies referenced
earlier to essentially no engraftment at 100 cGy TBI delivered
at a rate of 7 cGy/minute [1,2]. According to our data, in dogs
receiving 150 cGy TBI, the rate of stable engraftment was 50%
in those treated at a dose rate of 7 cGy/minute and 38% in
those treated at a dose rate of 70 cGy/minute, suggesting that
engraftment success is linear for a TBI dose of 200 cGy and
lower regardless of dose rate.
The development of nonmyeloablative conditioning
regimens represents a milestone in the treatment of malig-
nant and nonmalignant hematologic diseases with alloge-
neic HCT. Various regimens using this platform have
extended our ability to treat patients in advanced age groups,
as well as patients with comorbidities who cannot tolerate
the morbidity and mortality associated with high-intensity
radiation conditioning regimens. Protocols designed to
further reduce or eliminate radiation are aimed at allaying
short-term and long-term toxicities, including secondary
cancer. Althoughwewere unsuccessful in breaching the 100-
cGy TBI barrier with a 70-cGy/minute dose rate, our ﬁndings
suggest that treatment at this dose rate may be safely
translated to the clinics in which rates of 7 to 10 cGy/minute
are used today. An increased dose rate reduces the time that
patients must endure the radiation procedure, improves
treatment efﬁciency, and reduces staff time in operating the
linear accelerator.
In conclusion, we have shown that the higher dose rate of
70 cGy/minute is well tolerated in the DLA-identical non-
myeloablative HCTmodel. However, this higher dose rate has
no beneﬁt for engraftment.ACKNOWLEDGMENTS
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